ACRSAclaris Therapeutics, Inc.
$3.78+105% 1Y
$3.78
$1.8152 weeks$6.54
Is the price fair?
What ACRS's price assumes
Aclaris Therapeutics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 57.7× revenue.
57.7
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 3.36
Price / book · as of 2026-Q1
Details›
- Price / bookas of 2026-Q1
- 3.36
- EV / EBIToperating margin −1050%: the multiple describes the denominator
- not meaningful
- Market capitalisation
- $528M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.